Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report

Jing Wu(Nanjing Medical University), Qian Li(Soochow University), Xi Guo(Zhongshan Hospital), Yang You(East China University of Science and Technology), Qi Zhang(Sun Yat-sen University), Chenlu Zhang(Northwestern University), Rongyuan Zhuang(Zhongshan Hospital), Yuhong Zhou(Sun Yat-sen University)
Annals of Translational Medicine
March 1, 2022
Cited by 7


Related Papers